Healthcare and Medical

home | healthcare and medical | market report

Print Friendly

Pipeline and Commercial Insight - Urinary Incontinence - Lifecycle management strategies retain mid-term market growth (Datamonitor)

Market: Healthcare and Medical
Published Date: 26/12/2007
Report Title: Pipeline and Commercial Insight - Urinary Incontinence - Lifecycle management strategies retain mid-term market growth
Table of Contents: View Table of Contents
Report Type: Market Report
Country: Global
Number of Pages: 185

Introduction

The UI market is set to continue to grow over the next 6 years, reaching over $2.5 billion in 2012, a 68% increase from 2006. Lifecycle management strategies, novel formulations and follow-on products will drive the majority of this growth, with key brands expected to be Pfizer's Detrol LA (tolterodine) and Toviaz (fesoterodine), GSK's Vesicare (solifenacin), and Novartis' Enablex (darifenacin).

Scope

Analysis of patient potential, unmet needs and clinical trial design in UI.

Overview of key marketed brands, late- and early-stage pipeline drugs, and cell therapies.

Indication-specific sales volume and value forecasts to 2016 of marketed brands, generics, and key late-stage pipeline drugs.

Identification of future market events that are expected to affect UI drug revenues.

Highlights

Pfizer's Detrol LA (tolterodine) will remain the market leading UI brand through to 2012 when it comes off patent. At this point Detrol LA will be followed by the other second generation anticholinergics, GSK's Vesicare (solifenacin), Novartis' Enablex (darifenacin) and Pfizer's chemical reformulation Toviaz (fesoterodine).

Following the patent expiry of the key brands, Detrol LA in 2012, and Enablex/Vesicare in 2015, a novel mechanism of action is required for long-term market growth. Examples of the possible mechanisms of action include the NK-1 antagonists and the adrenergic modulators.

This report identifies a great untapped patient base in the US stress urinary incontinence (SUI) market. A drug that could come into this market would benefit from exclusivity, being the only treatment approved for SUI in the US with a potential 28 million patient base.

Reasons to Purchase

Benchmark key late-stage UI pipeline compounds against current market leading brands.

Assess region-specific (US, Japan, 5EU) sales forecasts of key late-stage pipeline drugs and marketed brands.

Understand unmet needs and opportunities in the UI market based on key opinion leader comments.

Purchase Information

There are various ways to purchase products from our site. Select the report title(s) you are interested in, and add it to your basket. At the Checkout page, you will be requested to submit your details. You will then have the option to pay via various methods: Debit Card ; Credit Card ; Purchase via Invoice (inc. Purchase Order no. if required) and Paypal. Companiesandmarkets.com accepts Visa, MasterCard, Diners, American Express, JCB and all the major credit cards. Companiesandmarkets.com uses RBSWorldpay.

Once you have purchased your report(s), you will receive a confirmation email. You will then either be able to download your report(s) immediately from your Customer Area in PDF format, or the report(s) will be emailed to you directly, depending on the agreement we have with the publisher. Orders that are deliverable via email which are taken outside of working hours will be delivered next business day.

Please note, if you purchase by invoice, you will receive your report(s) once payment has been received. If you have any questions about how to order, please Contact Us.